AstraZeneca: Pipeline Diversification, Innovation & Geographic Market Expansion Powering Our ‘Outperform’ Rating!

AstraZeneca has reported its first quarter 2025 financial results, revealing a robust performance marked by a 10% increase in total revenue. The pharmaceutical giant’s growth was driven by rising demand for its innovative medicines, with core operating profit up by 12% and core EPS rising by 21%. This performance was partially bolstered by favorable tax settlements. The company secured 13 regulatory approvals across key regions for its diverse portfolio, emphasizing its ongoing focus on delivering high-value treatments and novel molecular entities (NMEs).